From the replies returned by twenty-five prominent German clinicians in response to questionnaires,1 it is evident that specific treatment of lobar pneumonia with immune serum has not as yet been generally accepted. Even in this country, an inquiry revealed that many physicians still rely on quinine derivatives and do not employ specific immune serum in treating lobar pneumonia. In view of the reports of Cole,2 Cecil and Sutliff,3 Park, Bullowa and Rosenbluth4 and others, showing the beneficial effects of type I serum in treating type I infections in a large number of patients, it seems unfortunate that quinine is still being used to the exclusion of specific serotherapy.
Quinine was introduced in the treatment of pneumonia about fifty years ago, chiefly by Jürgenson and Aufrecht. A new compound, ethylhydrocupreine, was popularized by Morgenroth and his associates in 1911. Ethylhydrocupreine is more pneumococcicidal than quinine in vitro
REIMANN HA, MOEN JK. QUININE DERIVATIVES AND SPECIFIC IMMUNE SERUM IN THE TREATMENT OF PNEUMOCOCCUS INFECTION. Arch Intern Med (Chic). 1932;50(2):276–282. doi:10.1001/archinte.1932.00150150108011
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: